Characteristics | Patients n = 90 | |
---|---|---|
n | % | |
Age, years | ||
Median | 59 | – |
Range | 38–89 | – |
< 65 | 63 | 70 |
≥ 65 | 27 | 30 |
Sex | ||
Male | 57 | 63.3 |
Female | 33 | 36.7 |
ECOG performance status | ||
0 | 44 | 48.9 |
1 | 27 | 30.0 |
2 | 19 | 21.1 |
Histology | ||
Adenocarcinoma | 89 | 98.9 |
Adenosquamous carcinoma | 1 | 1.1 |
Tumor site | ||
Head-uncinate process | 41 | 45.6 |
Body-tail | 47 | 52.2 |
Multifocal | 2 | 2.2 |
Synchronous disease | ||
Yes | 47 | 64.4 |
No | 26 | 35.6 |
No. of metastatic sites | ||
1–2 | 61 | 83.6 |
3–4 | 12 | 16.4 |
Localization of metastasis | ||
Liver | 61 | 67.8 |
Peritoneal | 13 | 14.4 |
Lung | 6 | 6.7 |
Bones | 2 | 2.2 |
Local recurrence (including regional lymph node metastases) | 17 | 18.9 |
Previous treatments | ||
Radical surgery | 43 | 47.8 |
Adjuvant chemotherapy | 24 | 26.7 |
Ca19.9 (KU/L) | ||
≤ ULN | 15 | 16.7 |
> ULN | 75 | 83.3 |
Biliary stent | ||
Yes | 3 | 3.3 |
No | 87 | 96.7 |
HDL-C (mmol/L) | ||
> 0.9 | 77 | 85.6 |
≤ 0.9 | 13 | 14.4 |